Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pfizer’s $16 Billion Purchase|of Hospira Cleared by FTC

WASHINGTON (CN) - Pfizer will sell off rights to four drugs to clear its $16 billion acquisition of Hospira of antitrust concerns, the FTC said in a settled complaint.

Pfizer will divest itself of assets and rights to its generic acetylcysteine inhalation solution, and to three injectable Hospira drugs: clindamycin phosphate, an antibiotic; voriconazole, an anti-fungal drug; and melphalan hydrochloride, a chemotherapy drug. All four come in branded and generic versions.

Alvogen, a U.S.-based generic drugmaker, is expected to buy rights to all the drugs.

The companies will have three years to complete the divestitures.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...